Valuation: HLS Therapeutics Inc.

Market Cap 91.92M 79.61M 74.21M 68.25M 129M 8.74B 130M 872M 342M 4.37B 345M 338M 14.48B P/E 2026 *
-14.7x
P/E 2027 * -98x
Enterprise Value 91.92M 79.61M 74.21M 68.25M 129M 8.74B 130M 872M 342M 4.37B 345M 338M 14.48B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.43x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 week-3.06%
Current month-1.90%
1 month-1.90%
3 months-12.53%
6 months-8.44%
Current year-14.52%
1 week 4.08
Extreme 4.08
4.21
1 month 4.03
Extreme 4.03
4.39
Current year 4
Extreme 4
5.25
1 year 4
Extreme 4
5.76
3 years 3
Extreme 3
5.95
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 30/04/2023
Director of Finance/CFO 61 25/01/2024
Chief Tech/Sci/R&D Officer 61 31/05/2014
Director TitleAgeSince
Director/Board Member 58 11/03/2018
Chairman 48 21/06/2023
Director/Board Member 65 31/12/2020
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Option

Chief Financial Officer

50,000 0.1599%
26/06/26 Option

Chief Technology Officer

12,000 0.0384%
16/06/26 Buy

Chief Financial Officer

4,000 0.0128%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.06%-17.60%-30.41% 91.92M
+5.64%-1.28%+23.64%+107.99% 103B
+2.43%+4.41%+51.18%+162.17% 56.03B
+0.34%+1.01%+3.46%+278.48% 24.18B
-1.02%-0.84%-14.40%-17.62% 8.2B
-2.00%-4.55%-38.45%-32.35% 7.25B
-0.93%-3.06%-9.18%-17.94% 6.87B
-0.60%-1.14%+20.99%+18.57% 6.17B
+0.83%-2.97%-0.99%+23.38% 5.22B
-2.96%-4.10%-9.24%-8.39% 3.63B
Average +0.16%-1.99%+0.94%+48.39% 22.03B
Weighted average by Cap. +3.10%-0.01%+22.73%+120.78%

Financials

2026 *2027 *
Net sales 58.03M 50.26M 46.85M 43.09M 81.35M 5.52B 82.26M 551M 216M 2.76B 218M 213M 9.14B 64.31M 55.7M 51.92M 47.76M 90.16M 6.12B 91.16M 610M 239M 3.06B 242M 236M 10.13B
Net income -6.26M -5.43M -5.06M -4.65M -8.78M -596M -8.88M -59.43M -23.33M -298M -23.53M -23.01M -987M -1.05M -909K -848K -780K -1.47M -99.84M -1.49M -9.96M -3.91M -49.96M -3.94M -3.86M -165M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
05/08/26 CA$4.120 0.00% 315
04/08/26 CA$4.120 -1.90% 504
31/07/26 CA$4.200 0.00% 5,000
30/07/26 CA$4.200 -1.18% 12,652
29/07/26 CA$4.250 +0.95% 6,249
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.939USD
Average target price
5.179USD
Spread / Average Target
+76.22%

Quarterly revenue - Rate of surprise